QPPV.COM KNOWLEDGE ASSESSMENT

Garetosmab: Classification, Mechanism, Evidence and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Garetosmab: Classification, Mechanism, Evidence and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best reflects the article's approach to increased hair growth or acne compared with serious infection or clinically significant bleeding?

All should be treated as equivalent in clinical significance because they are adverse reactions. Cosmetic effects should be documented for onset and severity, without assuming they have the same medical significance as serious infection or bleeding. Hair growth and acne should not be recorded because they are not serious. Infection and bleeding should be recorded only if they lead to hospitalisation.

Question 2 of 10 Which description best explains the therapeutic rationale for garetosmab in FOP?

It neutralises activin A to reduce signalling through mutant ACVR1 that contributes to inappropriate bone formation. It removes mature heterotopic bone by directly dissolving mineralised tissue. It corrects the underlying ACVR1 genetic variant in affected cells. It prevents all tissue injury that could otherwise trigger an FOP flare.

Question 3 of 10 Which statement accurately reflects the U.S. dose guidance described in the article?

The recommended starting dose is 3 mg/kg every four weeks, with escalation to 10 mg/kg if tolerated. The recommended starting dose is 10 mg/kg every four weeks, with reduction to 3 mg/kg every four weeks if 10 mg/kg is not tolerated. The dose is selected solely according to the number of existing HO lesions. The 3 mg/kg and 10 mg/kg doses are stated to be interchangeable in all clinical circumstances.

Question 4 of 10 What is the most appropriate regulatory interpretation of the article's U.S. indication for an EU pharmacovigilance professional?

The U.S. authorisation automatically establishes the same indication and dose in the EU. The article describes U.S. regulatory status; indication and dosing should not be assumed to be identical in other jurisdictions. The U.S. indication has no relevance to safety case assessment. The U.S. authorisation means local prescribing information is no longer needed.

Question 5 of 10 Which measure was the primary efficacy endpoint in the study supporting the 2026 authorisation?

Total lesion activity by PET-CT Number of new HO lesions detected by full-body low-dose CT Change in serum activin A concentration alone Patient-reported pain intensity at the end of treatment

Question 6 of 10 An infection arises, is treated with an invasive procedure, and is followed by HO in the same region. How should the case be structured?

As one undifferentiated event with a single onset date As a sequence with separate components and chronology for the infection, procedure-related tissue trauma and subsequent HO As a procedure complication only, omitting the infection As an adverse reaction to garetosmab without documenting the disease context

Question 7 of 10 Which information is particularly relevant when assessing a report of epistaxis?

Duration, recurrence, haemodynamic effect, laboratory results, interventions, concomitant antithrombotic medicines, nasal trauma and other bleeding sites Only whether the patient had acne Only the number of infusions received, with no clinical details Whether the patient had a previous HO lesion in an unrelated anatomical site

Question 8 of 10 Which statement best describes the appropriate interpretation of flare and HO counts from the authorisation-supporting study?

They establish the exact number of flares or lesions an individual treated patient will experience. They are group-level findings from a small study and should not be converted into individual predictions. They show that clinician-assessed flares and imaging-confirmed lesions are interchangeable endpoints. They prove that no further post-authorisation case collection is needed.

Question 9 of 10 Which description best characterises the pivotal study supporting the 2026 U.S. authorisation, as summarised in the article?

An uncontrolled study of children followed for 28 weeks A randomised, double-blind, placebo-controlled study in 63 adults, with treatment every four weeks for 56 weeks A registry study comparing surgery with standard care in adults A phase 2 study in which all participants received garetosmab for 56 weeks

Question 10 of 10 Which plan best reflects the aggregate safety review priorities described in the article?

Review serious infections by site and intervention, clinically significant epistaxis, pregnancy exposure, and unexpected patterns of severe morbidity or mortality. Review only the frequency of acne because it is among the common adverse reactions. Exclude historical trial data and review only events occurring after authorisation. Treat every infection and every nosebleed as equally serious without reviewing clinical features.

QPPV.com

Garetosmab: Classification, Mechanism, Evidence and Pharmacovigilance — Knowledge Assessment

Cookie Settings